1. Search Result
Search Result
Isoforms Recommended: PAK4
Results for "

PAK4

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143490

    PAK Apoptosis Cancer
    PAK4-IN-2 is a highly potent PAK4 inhibitor with IC50 value of 2.7 nM. PAK4-IN-2 can arrest MV4-11 cells at G0/G1 phase and induce cell apoptosis. PAK4-IN-2 can be used for researching cancer .
    PAK4-IN-2
  • HY-125035
    LCH-7749944
    4 Publications Verification

    GNF-PF-2356

    PAK Apoptosis Cancer
    LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC50 of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis .
    LCH-7749944
  • HY-RS09993

    Small Interfering RNA (siRNA) Others

    PAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PAK4 Human Pre-designed siRNA Set A
    PAK4 Human Pre-designed siRNA Set A
  • HY-RS09994

    Small Interfering RNA (siRNA) Others

    Pak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak4 Mouse Pre-designed siRNA Set A
    Pak4 Mouse Pre-designed siRNA Set A
  • HY-RS09995

    Small Interfering RNA (siRNA) Others

    Pak4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak4 Rat Pre-designed siRNA Set A
    Pak4 Rat Pre-designed siRNA Set A
  • HY-159897

    PAK LIM Kinase (LIMK) Apoptosis Reactive Oxygen Species Cancer
    PAK4-IN-5 (Compound 12i) is a PAK4 inhibitor (IC50: 7.68 nM for PAK4, 1872.01 nM for PAK1). PAK4-IN-5 binds to PAK4 stably via multiple interactions. PAK4-IN-5 inhibits the proliferation and the migratory potential of MDA-MB-231 cells by inhibiting the phosphorylation of PAK4 and LIMK1. PAK4-IN-5 arrests cell cycle in the G0/G1 phase, induces apoptosis and ROS production. LD50: >500 mg/kg for mice (p.o.) .
    PAK4-IN-5
  • HY-130628

    PAK Cancer
    PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions .
    PAK4-IN-1
  • HY-156453

    PAK Apoptosis Cancer
    PAK4-IN-3(compound 27e) is aPAK4inhibitor, with theIC50of 10 nM.PAK4-IN-3shows antiproliferative activity against A549 cells with anIC50value of 0.61μM, and inducesapoptosisof A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1 .
    PAK4-IN-3
  • HY-117218

    PAK Cancer
    KY-04045 is a PAK4 specific inhibitor (IC50=8.7 μM) that can be used for the development of anticancer drugs targeting PAK4 .
    KY-04045
  • HY-124764

    PAK Cancer
    KY-04031 is a potent PAK4 inhibitor with IC50 of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion .
    KY-04031
  • HY-13007
    PF-3758309
    5+ Cited Publications

    PF-03758309

    PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309
  • HY-13007B

    PF-03758309 dihydrochloride

    PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 dihydrochloride
  • HY-13007A

    PF-03758309 hydrochloride

    PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 hydrochloride
  • HY-12793
    Padnarsertib
    1 Publications Verification

    KPT-9274

    PAK NAMPT Cancer
    Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC50s of <100 nM and 120 nM, respectively .
    Padnarsertib
  • HY-19538
    FRAX1036
    4 Publications Verification

    PAK Cancer
    FRAX1036 is a PAK inhibitor with Kis of 23.3 nM, 72.4 nM, and 2.4 μM for PAK1, PAK2 and PAK4, respectively.
    FRAX1036
  • HY-12632
    GNE 2861
    2 Publications Verification

    PAK Cancer
    GNE 2861 is a PAK inhibitor that displays group II selectivity. GNE 2861 inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively.
    GNE 2861
  • HY-15663
    IPA-3
    Maximum Cited Publications
    15 Publications Verification

    PAK Cancer
    IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).
    IPA-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: